Reckitt Benckiser sees a significant rise in shares following a legal win.
- Shares soared by over 10% after being cleared of liability in a case.
- The case involved accusations around preterm infant formula risks.
- A jury ruled in favour of Reckitt’s unit, Mead Johnson, and Abbott Labs.
- Reckitt’s sales had been affected by supply shortages in the third quarter.
Shares of Reckitt Benckiser surged by over 10% on Friday, marking a return to their highest value since March. This surge followed a favourable legal verdict where Reckitt was cleared of liability in a court case concerning its preterm infant formula. The case centred on allegations that Reckitt’s unit, Mead Johnson, alongside Abbott Labs, had failed to adequately warn of risks related to preterm formulas.
The legal proceedings concluded with a jury finding both Mead Johnson and Abbott Labs not responsible for a debilitating intestinal disease that afflicted a young boy. This decision prompted positive reactions from the companies involved. In a statement, Mead Johnson stated, ‘The ruling demonstrates that the claims in this case were not supported by the science or experts in the medical community,’ while Abbott Labs reinforced that the verdict supports the safety of preterm infant nutrition products.
This legal win arrives at a challenging time for Reckitt, as the company’s sales encountered disruptions in the third quarter due to supply shortages within its nutrition business sector, resulting in a 0.5% dip in net sales on a like-for-like basis. However, Reckitt reported a slight overall sales increase of 0.4% for the year up to 30 September.
Despite recent hurdles, the favourable court ruling provided a substantial boost to Reckitt’s market performance, restoring investor confidence and elevating its share price. This development underscores the importance of legal clarity and regulatory confidence in the pharmaceutical and consumer goods industry.
Reckitt Benckiser’s courtroom success has positively influenced its market standing, highlighting the vital role of legal outcomes in corporate health.
